Tirzepatide for managing overweight and obesity

Final draft guidance: 1

Final draft guidance (PDF 486 KB)

Committee papers (PDF 2.07 MB)

Committee papers (PDF 1.45 MB)

Committee papers (PDF 2.76 MB)

Public committee slides (PDF 725 KB)

Equality and health inequalities assessment (downloadable version) (PDF 195 KB)

Equality impact assessment (downloadable version) (PDF 195 KB)

Funding variation request

Funding Variation request (PDF 398 KB)

Annex B - Template treatment model for tirzepatide (PDF 227 KB)

Annex C - Impact of tirzepatide recommendation without variation (PDF 118 KB)

Annex D - Implementation Proposal (PDF 212 KB)

Annex E - Summary of Equalities Considerations (PDF 133 KB)

Annex F - ICB survey analysis (PDF 252 KB)

Annex G - Specialist Weight Management Service survey (PDF 140 KB)

Appendix 2 - Treatment Model (PDF 427 KB)

Draft guidance

Draft guidance (online commenting)

Draft guidance (PDF version) (PDF 457 KB)

Committee papers (PDF 15.27 MB)

Public committee slides - ACM1 (PDF 2.32 MB)

Public committee slides - ACM2 (PDF 913 KB)

Equality impact assessment (PDF 163 KB)

Committee meeting: 2

Register of interests (PDF 304 KB)

Final scope (PDF 210 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 464 KB)

Equality impact assessment (Scoping) (PDF 142 KB)

Final stakeholder list (MSWord 45 KB)

Draft scope post referral (PDF 195 KB)

Draft matrix post referral (PDF 156 KB)